CStone Pharmaceuticals CSPHF
0.76 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.9108 Day range 0.9109
0.595 52-week range 1.01
- YTD
- -15.45%
- 1 year
- -15.45%
- Market cap
- 1.20B
- EPS (ttm)
- -0.04
- YTD return
- -15.45%
- 1-year return
- -15.45%
- Volume
- 2.00K
- Avg volume
- 1.01K
- Open
- 0.9108
- Previous close
- 0.755
- Day's range
- 0.9108 – 0.9109
- 52-week range
- 0.595 – 1.01
- Earnings date
- Aug 20, 2026
2Y +0.4930 (+188.17%)
Next earnings
Aug 20, 2026
Expected Aug 20, 2026. Consensus EPS estimate -0.02796.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 20, 2026 | Jun 30, 2026 | -0.02796 | — | — | — |
| Mar 26, 2026 | Dec 31, 2025 | -0.00715 | -0.01716 | -0.01 | -140.00% |
| Mar 25, 2026 | Mar 31, 2026 | -0.12691 | — | — | — |
| Aug 14, 2025 | Jun 30, 2025 | -0.01396 | -0.01434 | 0.00 | -2.72% |
| Mar 25, 2025 | Oct 7, 2025 | -0.00411 | -0.01096 | -0.01 | -166.67% |
| Dec 31, 2024 | Dec 31, 2024 | — | -0.01147 | — | — |
News
CStone and Kimia Therapeutics Enter Clinical Development Collaboration to Advance a Novel Drug Candidate Targeting Repair Pathways Critical for Solid Tumor Survival 
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand 
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept 
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3) 
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0 
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) 
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
Your note
Sign in to keep a note on CSPHF — it syncs with the Stock Master app.